Evidence map›Paper›PMID 41266347›Full record

ArticleNPJ breast cancer2025

Early tumor volume reduction by breast DCE MRI predicts pathologic complete response to neoadjuvant therapy in triple negative breast cancer.

Mary S Guirguis, Beatriz E Adrada, Clinton Yam, Debu Tripathy, Rosalind Candelaria, Wei Yang, Miral Patel, Tanya Moseley, Frances Perez, Gary J Whitman and 20 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ breast cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02276443 (ARTEMIS), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02276443 naactive not recruitingnot on this map

ARTEMIS: A Robust TNBC Evaluation FraMework to Improve Survival

TypeinterventionalSponsorM.D. Anderson Cancer CenterRan2015 to 2026Enrolled798ConditionsInvasive Breast Carcinoma, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7ArmsChemotherapy, Immunotherapy, Laboratory Biomarker Analysis, Lymph Node Biopsy, Ultrasonography
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors.

Mary S GuirguisDepartment of Breast Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Beatriz E AdradaDepartment of Breast Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Clinton YamDepartment of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-0809-0851
Debu TripathyDepartment of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-5711-2404
Rosalind CandelariaDepartment of Breast Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Wei YangDepartment of Breast Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Miral PatelDepartment of Breast Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Tanya MoseleyDepartment of Breast Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Frances PerezDepartment of Breast Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Gary J WhitmanDepartment of Breast Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jessica W T LeungDepartment of Breast Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Huong Le-PetrossDepartment of Breast Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Deanna L LaneDepartment of Breast Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Lei HuoDepartment of Pathology, Anatomical, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0001-7533-9082
Jennifer K LittonDepartment of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Vicente ValeroDepartment of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Kelly K HuntDepartment of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0001-9156-8723
Banu ArunDepartment of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Rania MohamedDepartment of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jia SunDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Anil KorkutDepartment of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Zhan XuDepartment of Imaging Physics, The University of Texas MD Anderson Cancer, Houston, TX, USA.
Sanaz PashapoorDepartment of Breast Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jason WhiteDepartment of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jong Bum SonDepartment of Imaging Physics, The University of Texas MD Anderson Cancer, Houston, TX, USA.
Alastair ThompsonDepartment of Surgery, Baylor College of Medicine, Houston, TX, USA.
Peng WeiDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jingfei MaDepartment of Imaging Physics, The University of Texas MD Anderson Cancer, Houston, TX, USA.
Stacy MoulderEli Lilly and Company, Indianapolis, IN, USA.
Gaiane M RauchDepartment of Breast Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. GMRauch@mdanderson.org.ORCID http://orcid.org/0000-0003-2079-5202

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

Triple-negative breast cancer (TNBC) is a heterogeneous disease with variable response to neoadjuvant systemic therapy (NAST). Patients with pathologic complete response (pCR) following NAST have improved survival. Our goal was to establish readily accessible imaging biomarker to identify which TNBC patients will have pCR. Building on prior favorable results in the literature, we hypothesized that manually measured tumor volume changes at DCE-MRI may predict pCR early during NAST. This prospective study included 287 stage I-III TNBC patients who underwent DCE-MRI at baseline, after two and four cycles of NAST, with pCR accessed at surgery (NCT02276443). Tumor volume and percentage tumor volume reduction were calculated, and their correlation with pCR was evaluated. Our study showed that manually extracted tumor volume changes from DCE-MRI early during NAST were able to predict pCR with high accuracy and can serve as a clinically relevant imaging biomarker for prediction of NAST response in TNBC patients.

Identifiers

PMID41266347
PMCPMC12635395

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.